AI generated summary of Pubmed citation/abstract with PMID 38093310

https://pubmed.ncbi.nlm.nih.gov/38093310

In venous thromboembolic disease, a study found no difference in survival or reduction of new thromboembolic events between rivaroxaban and warfarin, but a lower risk of major bleeding with rivaroxaban at 12 months.